{
    "nctId": "NCT00193206",
    "briefTitle": "Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer",
    "officialTitle": "Phase II Trial of Dose Dense Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 123,
    "primaryOutcomeMeasure": "Pathologic Complete Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\nTo be included in this study, you must meet the following criteria:\n\n* Locally advanced/inflammatory adenocarcinoma of the breast\n* 18 years of age or older\n* Normal heart function\n* Able to perform activities of daily living with minimal assistance\n* No prior chemotherapy for breast cancer\n* Adequate bone marrow, liver and kidney function\n* No evidence or history of significant cardiovascular abnormalities\n* Sentinel node or axillary dissection\n* Sign an informed consent form\n\nExclusion Criteria:\n\nYou cannot participate in this study if any of the following apply to you:\n\n* Pregnant or breast feeding\n* History of heart disease with congestive heart failure\n* Heart attack within the previous 6 months\n* Prior chemotherapy or hormone therapy for breast cancer\n* History of active uncontrolled infection\n\nPlease note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}